<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-86525</identifier>
<setSpec>1134-3230</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Costs analysis of type 2 diabetes mellitus treatment with insulin glargine or detemir</dc:title>
<dc:description xml:lang="en">Introduction: Large published data suggested that some patients initiatingwith the recommended once daily insulin detemir administration require twicedaily dosing to optimise blood glucose control. Therefore the clinical outcomein this selected population was tested in a randomized controlled trial. Objective:To compare the costs of two treatments of type 2 diabetes mellitus, insulinglargine and insulin detemir, in patients with type 2 diabetes not controlledwith oral antidiabetic agents. Methods: Costs-offset analysis was modelledfrom the Spanish National Health System perspective, taking into account thehealth direct costs. A simulation of resources use related with glargine and detemirin type 2 diabetes treatment was performed, taking into account insulinadministered doses, utilization of test strips for glycemia control and disposableneedles used. The glargine and detemir doses were obtained from one clinicaltrial comparing both insulins for 24 weeks. The test strips and disposableneed les use were estimated from the Spanish clinical practice. Unit costs weretaken from Spanish sources and databases. Results: Lower daily doses were administeredwith glargine than with detemir. Therefore, the use of glargine insteaddetemir would result in a lower daily cost of insulin treatment, and alower use of test strips and disposable needles. As a consequence, the glargineuse would result in an annual saving of 765.03 &#128; for a patient with type 2diabetes, 43.3% savings with glargine versus detemir. According to the sensitivityanalysis, the annual saving for a patient treated with glargine was between646.05 and 810.55 &#128;. Conclusions: According to this model, in the abovementioned population, glargine insulin is a more cost-effective treatment thandetemir insulin, with lower annual treatment costs(AU)</dc:description>
<dc:creator>Álvarez Guisasola, F</dc:creator>
<dc:creator>Rubio-Terrés, C</dc:creator>
<dc:creator>García Coscolín, T</dc:creator>
<dc:creator>Betegón Nicolás, L</dc:creator>
<dc:creator>Mauricio Puente, D</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Conclusiones: Deacuerdo con el presente modelo, en la población estudiada la insulina glarginaes un tratamiento de la diabetes tipo 2 más coste-efectiva que la insulina detemiry se asocia a unos menores costes anuales de tratamiento(AU)</dc:description>
<dc:source>Av. diabetol;26(6): 430-435, nov.-dic. 2010. tab</dc:source>
<dc:identifier>ibc-86525</dc:identifier>
<dc:title xml:lang="es">Análisis de costes del tratamiento de la diabetes mellitus tipo 2 con insulina glargina o detemir</dc:title>
<dc:subject>^d12368^s22002</dc:subject>
<dc:subject>^d3942^s22053</dc:subject>
<dc:subject>^d14190^s22039</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d12368^s29165</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d3380^s22045</dc:subject>
<dc:subject>^d14190^s22074</dc:subject>
<dc:type>article</dc:type>
<dc:date>201012</dc:date>
</metadata>
</record>
</ibecs-document>
